Novartis cut its mid-term sales growth target as blockbuster patents expire

Summary
Peak sales guidance is higher for Kesimpta, Scemblix and Leqvio, and Novartis said its core margin is on track to return to 40% or higher by 2029
Description from Quartz.
Who is covering this
-
Novartis cut its mid-term sales growth target as blockbuster patents expire
Peak sales guidance is higher for Kesimpta, Scemblix and Leqvio, and Novartis said its core margin is on track to return to 40% or higher by 2029
Comments
Comments need JavaScript.